Sevilla

• A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in … Ended
  2024-512158-12-00 5 2018-12-14 Bladder Cancer Muscle-Invasive Bladder Cancer
• Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended
  2024-515040-23-00 4 2018-11-26 Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously tre
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv … Ended
  2023-508955-37-00 5 2018-10-10 Moderate to severe atopic dermatitis
• A Study to Assess Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small … Ended
  2023-508083-30-00 4 2018-07-19 Non-small cell lung cancer (NSCLC)
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemothe … Ended
  2023-504209-35-00 5 2018-04-04 Early-Stage Resectable Non-small cell lung cancer (NSCLC)
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc … Ended
  2024-513167-68-00 5 2017-11-29 endometrial cancer
• A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended
  2023-509711-83-00 5 2017-10-27 Advanced or Metastatic Renal Cell Carcinoma
• CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 Ended
  2022-501784-40-00 5 2017-05-26 Untreated Unresectable or Metastatic Urothelial Cancer
• Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER … Ended
  2024-514999-41-00 4 2017-04-28 HER2 negative metastatic breast cancer (MBC) with nervous system invol
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma
• A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung … Ended
  2022-501360-18-00 5 2017-03-15 Early Stage Non-Small Cell Lung Cancer (NSCLC)
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 5 2017-03-07 Triple Negative Breast Cancer (TNBC)
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar … Ended
  2023-508010-42-00 5 2016-09-14 Homologous recombination deficiency advanced ovarian cancer
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplification Ended
  2024-512003-39-00 4 2016-07-18 Lung Cancer
• Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patien … Ended
  2024-515394-10-00 9 2016-04-26 Selected Advanced Solid Tumors
• Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg … Ended
  2024-516132-10-00 4 2016-02-05 Metastatic breast cancer
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic … Ended
  2024-514269-20-00 5 2015-05-06 Metastatic Non-Small Cell Lung Cancer
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended
  2023-504034-22-00 5 2014-12-18 Chronic Lymphocytic Leukemia (CLL)
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 5 2014-11-19 Advanced or metastatic renal cell carcinoma

Showing 1,585–1,608 of 1,630 trials